Distinct signaling from stem cell factor and erythropoietin in HCD57 cells

J Biol Chem. 1997 Mar 14;272(11):6850-3. doi: 10.1074/jbc.272.11.6850.

Abstract

A recent report (Wu, H., Klingmuller, U., Besmer, P., and Lodish, H. F. (1995) Nature 377, 242-246) documents the interaction of the erythropoietin (EPO) receptor (EPOR) with the stem cell factor (SCF) receptor (c-KIT) and suggests that SCF acts through the EPOR. To elucidate the ability of SCF to affect the erythropoietin signaling pathway, we studied the effect of SCF on EPOR phosphorylation, SHC/ERK-1 activity, and cell proliferation and apoptosis in EPO-dependent HCD57 cells. Treatment of these cells with SCF resulted in phosphorylation of the EPOR. However, SCF-dependent phosphorylation of the EPOR did not initiate an EPO-like intracellular signal. SCF induced proliferation, SHC phosphorylation, and activation of ERK-1 but did not activate the JAK/STAT pathway. SCF stimulated SHC phosphorylation and ERK-1 activation independent of the EPOR in cells where the EPOR was down-regulated; the presence of the EPOR appeared to facilitate SCF activation of SHC and ERK-1. Furthermore, treatment of HCD57 cells with SCF increased cell number over a 3-day treatment, but apoptosis was observed in these cells. These data may illustrate two distinct pathways for erythroid cell proliferation and prevention of apoptosis in response to EPO, thereby providing a system to discriminate these intracellular signals.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Apoptosis / drug effects
  • Cell Division / drug effects
  • Erythropoietin / metabolism*
  • Erythropoietin / pharmacology
  • Leukemia, Erythroblastic, Acute / metabolism*
  • Leukemia, Erythroblastic, Acute / pathology
  • Phosphorylation
  • Signal Transduction / drug effects*
  • Stem Cell Factor / metabolism*
  • Stem Cell Factor / pharmacology
  • Tumor Cells, Cultured
  • Tyrosine / metabolism

Substances

  • Stem Cell Factor
  • Erythropoietin
  • Tyrosine